BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21820898)

  • 1. The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents.
    Haney KM; Zhang F; Arnatt CK; Yuan Y; Li G; Ware JL; Gewirtz DA; Zhang Y
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5159-63. PubMed ID: 21820898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.
    Zhang F; Arnatt CK; Haney KM; Fang HC; Bajacan JE; Richardson AC; Ware JL; Zhang Y
    Eur J Med Chem; 2012 Sep; 55():395-408. PubMed ID: 22901310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents.
    Xu GG; Zaidi SA; Zhang F; Singh S; Raborg TJ; Yuan Y; Zhang Y
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3721-5. PubMed ID: 26096680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents.
    Arnatt CK; Zaidi SA; Zhang Z; Li G; Richardson AC; Ware JL; Zhang Y
    Eur J Med Chem; 2013 Nov; 69():647-58. PubMed ID: 24095757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents.
    Zhang Y; Arnatt CK; Zhang F; Wang J; Haney KM; Fang X
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5093-7. PubMed ID: 22770928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents.
    Zhang X; Haney KM; Richardson AC; Wilson E; Gewirtz DA; Ware JL; Zehner ZE; Zhang Y
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4627-30. PubMed ID: 20579875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents.
    Arnatt CK; Adams JL; Zhang Z; Haney KM; Li G; Zhang Y
    Bioorg Med Chem Lett; 2014 May; 24(10):2319-23. PubMed ID: 24731275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total synthesis of anibamine, a novel natural product as a chemokine receptor CCR5 antagonist.
    Li G; Watson K; Buckheit RW; Zhang Y
    Org Lett; 2007 May; 9(10):2043-6. PubMed ID: 17447782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
    Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
    Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
    Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
    J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine.
    White AW; Carpenter N; Lottin JR; McClelland RA; Nicholson RI
    Eur J Med Chem; 2012 Oct; 56():246-53. PubMed ID: 22995819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents.
    Li W; Zhai X; Zhong Z; Li G; Pu Y; Gong P
    Arch Pharm (Weinheim); 2011 Jun; 344(6):349-57. PubMed ID: 21433057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity.
    Meimetis LG; Williams DE; Mawji NR; Banuelos CA; Lal AA; Park JJ; Tien AH; Fernandez JG; de Voogd NJ; Sadar MD; Andersen RJ
    J Med Chem; 2012 Jan; 55(1):503-14. PubMed ID: 22148427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
    Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical modification and organelle-specific localization of orlistat-like natural-product-based probes.
    Yang PY; Liu K; Zhang C; Chen GY; Shen Y; Ngai MH; Lear MJ; Yao SQ
    Chem Asian J; 2011 Oct; 6(10):2762-75. PubMed ID: 21744505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 6-[(hetero)arylamino]thieno[3,2-b]pyridines: synthesis and antitumoral activities.
    Queiroz MJ; Calhelha RC; Vale-Silva LA; Pinto E; São-José Nascimento M
    Eur J Med Chem; 2010 Dec; 45(12):5732-8. PubMed ID: 20934235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
    Vaday GG; Peehl DM; Kadam PA; Lawrence DM
    Prostate; 2006 Feb; 66(2):124-34. PubMed ID: 16161154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and potency optimization of 2-amino-5-arylmethyl-1,3-thiazole derivatives as potential therapeutic agents for prostate cancer.
    Krasavin M; Karapetian R; Konstantinov I; Gezentsvey Y; Bukhryakov K; Godovykh E; Soldatkina O; Lavrovsky Y; Sosnov AV; Gakh AA
    Arch Pharm (Weinheim); 2009 Jul; 342(7):420-7. PubMed ID: 19544302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
    Bolognese A; Correale G; Manfra M; Lavecchia A; Novellino E; Pepe S
    J Med Chem; 2006 Aug; 49(17):5110-8. PubMed ID: 16913700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.